Oncolytics Biotech (NASDAQ:ONCY) Cut to Moderate Buy at Leede Financial

Leede Financial cut shares of Oncolytics Biotech (NASDAQ:ONCY) from a strong-buy rating to a moderate buy rating in a research note issued to investors on Wednesday,Zacks.com reports.

Separately, HC Wainwright restated a “buy” rating and issued a $5.00 price objective on shares of Oncolytics Biotech in a research report on Thursday.

Oncolytics Biotech Stock Performance

Shares of Oncolytics Biotech stock traded down $0.03 during trading hours on Wednesday, hitting $0.98. The company’s stock had a trading volume of 245,358 shares, compared to its average volume of 328,224. The business has a 50 day moving average price of $1.09 and a two-hundred day moving average price of $1.06. Oncolytics Biotech has a 12-month low of $0.84 and a 12-month high of $1.75. The company has a market cap of $75.53 million, a PE ratio of -3.63 and a beta of 1.69.

Institutional Investors Weigh In On Oncolytics Biotech

A hedge fund recently bought a new stake in Oncolytics Biotech stock. Virtu Financial LLC acquired a new position in shares of Oncolytics Biotech Inc. (NASDAQ:ONCY) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned about 0.07% of Oncolytics Biotech at the end of the most recent reporting period. 6.82% of the stock is currently owned by hedge funds and other institutional investors.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.